| |
| |
|
| Insider
Information: |
Aselage Steve |
| Relationship: |
Director |
| City: |
Fremont |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
293,421 |
|
|
Indirect Shares
|
19,500 |
|
|
| Direct
Value |
$6,673,357 |
|
|
|
Indirect Value
|
$113,100 |
|
|
| Total
Shares |
312,921 |
|
|
| Total
Value |
$6,786,457 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
5
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
4
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-4.0
|
1.5
|
| Percentage
Gain/Loss : |
 -31.1%
|
 62.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cti Biopharma Corporation |
CTIC |
EVP, Global Commercial... |
2005-06-30 |
24,133 |
2004-08-03 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Business Of... |
2012-07-02 |
59,030 |
2006-04-28 |
0 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Director |
2022-05-11 |
146,919 |
2021-11-05 |
19,500 |
Premium* |
|
|
Acer Therapeutics Inc |
ACER |
Director |
2023-11-17 |
0 |
2017-09-19 |
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2023-06-13 |
63,339 |
2019-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ACER |
Acer Therapeutics Inc |
Director |
– • – |
2023-11-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(483,741) |
0 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
63,339 |
0 |
- |
|
| ACER |
Acer Therapeutics Inc |
Director |
– • – |
2022-11-29 |
4 |
B |
$1.22 |
$500,000 |
D/D |
409,836 |
483,741 |
2.39 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2022-05-31 |
4 |
A |
$9.31 |
$5,297 |
D/D |
569 |
33,728 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2022-05-11 |
4 |
S |
$21.92 |
$56,457 |
D/D |
(2,575) |
146,919 |
0 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2022-02-28 |
4 |
A |
$16.61 |
$5,000 |
D/D |
301 |
33,159 |
0 |
- |
|
| ACER |
Acer Therapeutics Inc |
Director |
– • – |
2021-12-10 |
4 |
B |
$2.04 |
$16,287 |
D/D |
7,984 |
73,905 |
2.39 |
% |
|
| ACER |
Acer Therapeutics Inc |
Director |
– • – |
2021-12-09 |
4 |
B |
$2.15 |
$4,334 |
D/D |
2,016 |
65,921 |
2.31 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2021-11-30 |
4 |
A |
$12.06 |
$4,993 |
D/D |
414 |
32,858 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-16 |
4 |
AS |
$29.39 |
$934,602 |
D/D |
(31,800) |
149,494 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-05 |
4 |
AS |
$26.23 |
$262,300 |
D/D |
(10,000) |
161,794 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-05 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
171,794 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-02 |
4 |
AS |
$30.00 |
$105,000 |
I/I |
(3,500) |
19,500 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-01 |
4 |
AS |
$29.48 |
$147,400 |
I/I |
(5,000) |
23,000 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-10-07 |
4 |
OE |
$16.23 |
$973,800 |
D/D |
60,000 |
249,794 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-10-07 |
4 |
AS |
$26.23 |
$1,574,760 |
D/D |
(60,000) |
189,794 |
0 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2021-08-31 |
4 |
A |
$15.92 |
$4,999 |
D/D |
314 |
32,444 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-07-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
161,794 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-07-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
3,000 |
28,000 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2021-05-28 |
4 |
A |
$15.77 |
$9,998 |
D/D |
634 |
32,130 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
189,794 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-05-11 |
4 |
S |
$19.58 |
$42,023 |
D/D |
(2,146) |
186,794 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-04-16 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
198,940 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-04-16 |
4 |
AS |
$26.23 |
$262,300 |
D/D |
(10,000) |
188,940 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-03-17 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
206,667 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
